10x Genomics (TXG) Gains from Investment Securities (2018 - 2026)

10x Genomics has disclosed Gains from Investment Securities across 9 years of filings, most recently posting -$278000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$278000.0, down 160.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$740000.0 (down 48.3% YoY), and the FY2023 annual result was -$1.7 million, down 143.77% from the prior year.
• Gains from Investment Securities came in at -$278000.0 for Q1 2026 at 10x Genomics, up from -$1.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.7 million in Q2 2022 to a low of -$12.9 million in Q3 2022.
• The 5-year median for Gains from Investment Securities is $369000.0 (2022), against an average of $137785.7.
• Across the five-year window, Gains from Investment Securities jumped 220.87% in 2022 and sank 3320.29% in 2023, its largest moves.
• 10x Genomics' Gains from Investment Securities stood at $276000.0 in 2022, then tumbled by 3320.29% to -$8.9 million in 2023, then surged by 89.19% to -$961000.0 in 2024, then sank by 37.15% to -$1.3 million in 2025, then surged by 78.91% to -$278000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$278000.0 (Q1 2026), -$1.3 million (Q3 2025), and $856000.0 (Q2 2025), per Business Quant data.